You are here: Industry Insights > MediciNova

News List

COVID-19 Vaccine Prototype for Successfully Induced Systemic Serum IgG in Mice americanpharmaceuticalreview
September 30, 2020
MediciNova announced its intranasal SARS-CoV-2 vaccine prototype for COVID-19, using BC-PIV technology, successfully induced systemic serum IgG and mucosal IgA neutralizing antibodies against the S1 antigen (Ag) of SARS-CoV-2 in mice.
MediciNova Announces Development Progress on Intranasal Formulation of COVID-19 Vaccine americanpharmaceuticalreview
September 02, 2020
MediciNova announced development progress on its intranasal SARS-CoV-2 vaccine for COVID-19 utilizing BC-PIV, a viral vector platform technology developed by Mie University and BioComo.
MediciNova Announces SARS-CoV-2 Vaccine Joint Development with BioComo, Mie University Japan americanpharmaceuticalreview
July 31, 2020
MediciNova announced an agreement with BioComo and Mie University for joint development of a SARS-CoV-2 vaccine using BC-PIV.
MediciNova Receives Notice of Allowance for Second Patent Covering Glioblastoma Treatment americanpharmaceuticalreview
April 24, 2020
MediciNova has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of glioblastoma.
MediciNova to Develop Severe Pneumonia, ARDS Treatment americanpharmaceuticalreview
March 11, 2020
MediciNova announced it plans to initiate development of MN-166 (ibudilast) for severe pneumonia and acute respiratory distress syndrome (ARDS).
MediciNova Announces Plans to Move Forward with a Phase 3 Trial of MN-166 (ibudilast) in ALS drugs
April 25, 2019
MediciNova Announces Plans to Move Forward with a Phase 3 Trial of MN-166 (ibudilast) in ALS.
MediciNova’s Drug Flunks Phase II Trial biospace
March 30, 2018
La Jolla, California-based MediciNova announced that its Phase II clinical trial of ibudilast (MN-166) failed to meet its primary endpoint for methamphetamine dependence.